Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM

Manmeet Ahluwalia

Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Jun 2017
Event	American Society of Clinical Oncology (ASCO) Annual Meeting - Chicago, IL Duration: Jun 1 2018 → …

Conference

Conference	American Society of Clinical Oncology (ASCO) Annual Meeting
Period	6/1/18 → …

Disciplines

Medicine and Health Sciences

Cite this

@conference{c7d19a4e21034cf3b326873de8c94c89,

title = "Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM",

author = "Manmeet Ahluwalia",

year = "2017",

month = jun,

language = "American English",

note = "American Society of Clinical Oncology (ASCO) Annual Meeting ; Conference date: 01-06-2018",

}

TY - CONF

T1 - Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM

AU - Ahluwalia, Manmeet

PY - 2017/6

Y1 - 2017/6

M3 - Presentation

T2 - American Society of Clinical Oncology (ASCO) Annual Meeting

Y2 - 1 June 2018

ER -